Podoplanin: A marker for reactive gliosis in gliomas and brain injury

Kushal Kolar, Moises Freitas-Andrade, John F. Bechberger, Harini Krishnan, Gary S. Goldberg, Christian C. Naus, Wun Chey Sin

Research output: Contribution to journalArticlepeer-review

31 Scopus citations

Abstract

Reactive astrogliosis is associated with many pathologic processes in the central nervous system, including gliomas. The glycoprotein podoplanin (PDPN) is upregulated in malignant gliomas. Using a syngeneic intracranial glioma mouse model, we show that PDPN is highly expressed in a subset of glial fibrillary acidic protein-positive astrocytes within and adjacent to gliomas. The expression of PDPN in tumor-associated reactive astrocytes was confirmed by its colocalization with the astrocytic marker S100β and with connexin43, a major astrocytic gap junction protein. To determine whether the increase in PDPN is a general feature of gliosis, we used 2 mouse models in which astrogliosis was induced either by a needle injury or ischemia and observed similar upregulation of PDPN in reactive astrocytes in both models. Astrocytic PDPN was also found to be coexpressed with nestin, an intermediate filament marker for neural stem/progenitor cells. Our findings confirm that expression of PDPN is part of the normal host response to brain injury and gliomas, and suggest that it may be a novel cell surface marker for a specific population of reactive astrocytes in the vicinity of gliomas and nonneoplastic brain lesions. The findings also highlight the heterogeneity of glial fibrillary acidic protein-positive astrocytes in reactive gliosis.

Original languageEnglish (US)
Pages (from-to)64-74
Number of pages11
JournalJournal of Neuropathology and Experimental Neurology
Volume74
Issue number1
DOIs
StatePublished - Jan 3 2015

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Neurology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'Podoplanin: A marker for reactive gliosis in gliomas and brain injury'. Together they form a unique fingerprint.

Cite this